Sichuan Hexie Shuangma (000935.SZ): The application for listing of acetic acid jableburi chemical raw materials has been approved.

Sichuan Hexie Shuangma (000935.SZ) announced that its controlling subsidiary, Hubei Jianxiang Biological Pharmaceutical Co., Ltd. (referred to as "Hubei Jianxiang"), recently obtained the approval notice for the market application of Leuprorelin Acetate issued by the National Medical Products Administration. The announcement shows that Leuprorelin Acetate is a gonadotropin-releasing hormone (GnRH) agonist, and continuous administration at therapeutic doses can effectively suppress the secretion of gonadotropins. Currently approved in China for the treatment of endometriosis, uterine fibroids, prostate cancer, premenopausal breast cancer with estrogen receptor positivity, and central precocious puberty.